# Liqtech International Inc: financial statements, quarterly

LIQT · Nasdaq · CIK 1307579 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/liqt.md) · [Financials](/companies/liqt/financials.md) · [Filings](/companies/liqt/filings.md) · [Insiders](/companies/liqt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/liqt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [5,070](/filings/0001437749-24-035290.md) | [3,930 d](/filings/0001437749-25-009832.md) | [4,235](/filings/0001437749-25-016825.md) | [4,485](/filings/0001437749-25-026498.md) | [2,478](/filings/0001437749-25-034985.md) | [3,406 d](/filings/0001437749-26-005983.md) | [4,618](/filings/0001437749-26-016536.md) | [4,957](/filings/0001437749-26-027154.md) | [3,807](/filings/0001437749-25-034985.md) | [3,125 d](/filings/0001437749-26-005983.md) | [4,136](/filings/0001437749-26-016536.md) | [4,364](/filings/0001437749-26-027154.md) |
| Cost of revenue | $k | [4,122](/filings/0001437749-24-035290.md) | [3,657 d](/filings/0001437749-25-009832.md) | [3,964](/filings/0001437749-25-016825.md) | [3,768](/filings/0001437749-25-026498.md) | [2,688](/filings/0001437749-25-034985.md) | [3,934 d](/filings/0001437749-26-005983.md) | [4,492](/filings/0001437749-26-016536.md) | [4,473](/filings/0001437749-26-027154.md) | [3,059](/filings/0001437749-25-034985.md) | [3,232 d](/filings/0001437749-26-005983.md) | [3,743](/filings/0001437749-26-016536.md) | [3,998](/filings/0001437749-26-027154.md) |
| Gross profit | $k | [949](/filings/0001437749-24-035290.md) | [273 d](/filings/0001437749-25-009832.md) | [271](/filings/0001437749-25-016825.md) | [717](/filings/0001437749-25-026498.md) | [(210)](/filings/0001437749-25-034985.md) | [(528) d](/filings/0001437749-26-005983.md) | [125](/filings/0001437749-26-016536.md) | [485](/filings/0001437749-26-027154.md) | [748](/filings/0001437749-25-034985.md) | [(107) d](/filings/0001437749-26-005983.md) | [394](/filings/0001437749-26-016536.md) | [366](/filings/0001437749-26-027154.md) |
| Research and development | $k | [429](/filings/0001437749-24-035290.md) | [288 d](/filings/0001437749-25-009832.md) | [255](/filings/0001437749-25-016825.md) | [407](/filings/0001437749-25-026498.md) | [278](/filings/0001437749-25-034985.md) | [412 d](/filings/0001437749-26-005983.md) | [230](/filings/0001437749-26-016536.md) | [243](/filings/0001437749-26-027154.md) | [269](/filings/0001437749-25-034985.md) | [422 d](/filings/0001437749-26-005983.md) | [276](/filings/0001437749-26-016536.md) | [272](/filings/0001437749-26-027154.md) |
| Operating income | $k | [(1,699)](/filings/0001437749-24-035290.md) | [(2,305) d](/filings/0001437749-25-009832.md) | [(2,046)](/filings/0001437749-25-016825.md) | [(2,087)](/filings/0001437749-25-026498.md) | [(2,590)](/filings/0001437749-25-034985.md) | [(2,765) d](/filings/0001437749-26-005983.md) | [(2,185)](/filings/0001437749-26-016536.md) | [(2,110)](/filings/0001437749-26-027154.md) | [(1,333)](/filings/0001437749-25-034985.md) | [(2,681) d](/filings/0001437749-26-005983.md) | [(2,277)](/filings/0001437749-26-016536.md) | [(2,332)](/filings/0001437749-26-027154.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [(14.5)](/filings/0001437749-24-035290.md) | [(163) d](/filings/0001437749-25-009832.md) | [(14.4)](/filings/0001437749-25-016825.md) | [(14.2)](/filings/0001437749-25-026498.md) | [(10.1)](/filings/0001437749-25-034985.md) | [(0.2) d](/filings/0001437749-26-005983.md) | [(0.3)](/filings/0001437749-26-016536.md) | [(0.4)](/filings/0001437749-26-027154.md) | [(0.4)](/filings/0001437749-25-034985.md) | [(0.4) d](/filings/0001437749-26-005983.md) | [(0.4)](/filings/0001437749-26-016536.md) | [(0.4)](/filings/0001437749-26-027154.md) |
| Net income | $k | [(1,414)](/filings/0001437749-24-035290.md) | [(3,212) d](/filings/0001437749-25-009832.md) | [(2,388)](/filings/0001437749-25-034985.md) | [(2,112)](/filings/0001437749-25-034985.md) | [(2,841)](/filings/0001437749-25-034985.md) | [(3,005) d](/filings/0001437749-26-005983.md) | [(2,351)](/filings/0001437749-26-027154.md) | [(2,152)](/filings/0001437749-26-027154.md) | [(1,432)](/filings/0001437749-25-034985.md) | [(2,592) d](/filings/0001437749-26-005983.md) | [(2,710)](/filings/0001437749-26-027154.md) | [(3,016)](/filings/0001437749-26-027154.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.25)](/filings/0001437749-24-035290.md) | not reported | [(0.41)](/filings/0001437749-25-016825.md) | [(0.36)](/filings/0001437749-25-026498.md) | [(0.49)](/filings/0001437749-25-034985.md) | not reported | [(0.25)](/filings/0001437749-26-016536.md) | [(0.14)](/filings/0001437749-26-027154.md) | [(0.15)](/filings/0001437749-25-034985.md) | not reported | [(0.28)](/filings/0001437749-26-016536.md) | [(0.14)](/filings/0001437749-26-027154.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.8](/filings/0001437749-23-031248.md) | [10.4](/filings/0001437749-24-009045.md) | [7.7](/filings/0001437749-24-016604.md) | [5.5](/filings/0001437749-24-026779.md) | [4.5](/filings/0001437749-24-035290.md) | not reported | not reported | not reported | not reported | [5.1](/filings/0001437749-26-005983.md) | [2.7](/filings/0001437749-26-016536.md) | not reported |
| Current assets | $m | [24.6](/filings/0001437749-23-031248.md) | [22.1](/filings/0001437749-25-009832.md) | [19.4](/filings/0001437749-24-016604.md) | [17.2](/filings/0001437749-24-026779.md) | [16.0](/filings/0001437749-24-035290.md) | [20.6](/filings/0001437749-26-005983.md) | [20.9](/filings/0001437749-25-016825.md) | [19.8](/filings/0001437749-25-026498.md) | [18.8](/filings/0001437749-25-034985.md) | [16.0](/filings/0001437749-26-027154.md) | [14.1](/filings/0001437749-26-016536.md) | [27.7](/filings/0001437749-26-027154.md) |
| Total assets | $m | [36.8](/filings/0001437749-23-031248.md) | [36.0](/filings/0001437749-25-009832.md) | [31.4](/filings/0001437749-24-016604.md) | [28.6](/filings/0001437749-24-026779.md) | [28.7](/filings/0001437749-24-035290.md) | [32.4](/filings/0001437749-26-005983.md) | [31.7](/filings/0001437749-25-026498.md) | [31.7](/filings/0001437749-25-026498.md) | [30.3](/filings/0001437749-25-034985.md) | [27.3](/filings/0001437749-26-027154.md) | [24.9](/filings/0001437749-26-016536.md) | [37.9](/filings/0001437749-26-027154.md) |
| Current liabilities | $m | [7.7](/filings/0001437749-23-031248.md) | [7.5](/filings/0001437749-25-009832.md) | [6.6](/filings/0001437749-24-016604.md) | [6.3](/filings/0001437749-24-026779.md) | [6.0](/filings/0001437749-24-035290.md) | [4.9](/filings/0001437749-26-005983.md) | [5.5](/filings/0001437749-25-016825.md) | [5.5](/filings/0001437749-25-026498.md) | [5.4](/filings/0001437749-25-034985.md) | [4.7](/filings/0001437749-26-027154.md) | [5.7](/filings/0001437749-26-016536.md) | [6.3](/filings/0001437749-26-027154.md) |
| Total liabilities | $m | [17.6](/filings/0001437749-23-031248.md) | [18.7](/filings/0001437749-25-009832.md) | [16.8](/filings/0001437749-24-016604.md) | [16.3](/filings/0001437749-24-026779.md) | [17.3](/filings/0001437749-24-035290.md) | [15.8](/filings/0001437749-26-005983.md) | [17.5](/filings/0001437749-25-016825.md) | [17.8](/filings/0001437749-25-026498.md) | [17.5](/filings/0001437749-25-034985.md) | [16.9](/filings/0001437749-26-027154.md) | [17.4](/filings/0001437749-26-016536.md) | [12.1](/filings/0001437749-26-027154.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [19.3](/filings/0001437749-24-035290.md) | [17.3](/filings/0001437749-25-009832.md) | [14.5](/filings/0001437749-24-035290.md) | [12.3](/filings/0001437749-24-035290.md) | [11.4](/filings/0001437749-24-035290.md) | [16.7](/filings/0001437749-26-005983.md) | [15.1](/filings/0001437749-25-016825.md) | [13.9](/filings/0001437749-25-026498.md) | [12.8](/filings/0001437749-25-034985.md) | [10.4](/filings/0001437749-26-027154.md) | [7.6](/filings/0001437749-26-016536.md) | [25.9](/filings/0001437749-26-027154.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [783 d](/filings/0001437749-24-035290.md) | [(1,210) d](/filings/0001437749-25-009832.md) | [(1,957)](/filings/0001437749-25-016825.md) | [(1,823) d](/filings/0001437749-25-026498.md) | [(1,749) d](/filings/0001437749-25-034985.md) | [(2,006) d](/filings/0001437749-26-005983.md) | [(1,297)](/filings/0001437749-26-016536.md) | [(1,611) d](/filings/0001437749-26-027154.md) | [(1,069) d](/filings/0001437749-25-034985.md) | [(2,131) d](/filings/0001437749-26-005983.md) | [(1,941)](/filings/0001437749-26-016536.md) | [(3,096) d](/filings/0001437749-26-027154.md) |
| Capital expenditure | $k | [1,971 d](/filings/0001437749-24-035290.md) | [632 d](/filings/0001437749-25-009832.md) | [389](/filings/0001437749-25-016825.md) | [223 d](/filings/0001437749-25-026498.md) | [365 d](/filings/0001437749-25-034985.md) | [390 d](/filings/0001437749-26-005983.md) | [163](/filings/0001437749-26-016536.md) | [(61.1) d](/filings/0001437749-26-027154.md) | [127 d](/filings/0001437749-25-034985.md) | [166 d](/filings/0001437749-26-005983.md) | [270](/filings/0001437749-26-016536.md) | [7.9 d](/filings/0001437749-26-027154.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.7](/filings/0001437749-21-011831.md) | [21.0](/filings/0001437749-20-017365.md) | [21.7](/filings/0001437749-20-023254.md) | [21.7](/filings/0001437749-22-012160.md) | [21.8](/filings/0001437749-22-020136.md) | [21.8](/filings/0001437749-22-026887.md) | [21.4](/filings/0001437749-23-013916.md) | [4.0](/filings/0001437749-23-023143.md) | [5.5](/filings/0001437749-23-031248.md) | [45.2](/filings/0001437749-23-013916.md) | [5.7](/filings/0001437749-23-023143.md) | [5.7](/filings/0001437749-23-031248.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,947,841 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027154.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.